BR0312288A - Derivados de amidas - Google Patents
Derivados de amidasInfo
- Publication number
- BR0312288A BR0312288A BR0312288-3A BR0312288A BR0312288A BR 0312288 A BR0312288 A BR 0312288A BR 0312288 A BR0312288 A BR 0312288A BR 0312288 A BR0312288 A BR 0312288A
- Authority
- BR
- Brazil
- Prior art keywords
- halogen
- present
- formula
- amide derivatives
- group
- Prior art date
Links
- 150000001408 amides Chemical class 0.000 title abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 abstract 1
- 229920000881 Modified starch Polymers 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 235000019426 modified starch Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"DERIVADOS DE AMIDAS". A presente invenção fornece um derivado de amida representado pela seguinte fórmula genérica [1]: onde R^ 1^ representa um grupo amino cíclico saturado, R^ 2^ representa alquila, halogênio ou halo-alquila, R^ 3^ representa hidrogênio ou halogênio, Het2 representa piridila ou pirimidinila, e Het1 representa um grupo da fórmula [6], ou um seu sal, e uma composição farmacêutica que compreende o mesmo como um ingrediente ativo. O composto da presente invenção é útil como um inibidor de tirosina cinase de BCR-ABL.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002189269 | 2002-06-28 | ||
JP2002305146 | 2002-10-18 | ||
JP2002377937 | 2002-12-26 | ||
PCT/JP2003/008192 WO2004002963A1 (ja) | 2002-06-28 | 2003-06-27 | アミド誘導体及び医薬 |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0312288A true BR0312288A (pt) | 2005-04-12 |
BRPI0312288B1 BRPI0312288B1 (pt) | 2019-01-02 |
BRPI0312288B8 BRPI0312288B8 (pt) | 2021-05-25 |
Family
ID=30003594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0312288A BRPI0312288B8 (pt) | 2002-06-28 | 2003-06-27 | derivados de amidas |
Country Status (15)
Country | Link |
---|---|
US (1) | US7494997B2 (pt) |
EP (1) | EP1533304B1 (pt) |
JP (1) | JP4552650B2 (pt) |
CN (1) | CN100343237C (pt) |
AT (1) | ATE447560T1 (pt) |
AU (1) | AU2003246100A1 (pt) |
BR (1) | BRPI0312288B8 (pt) |
CA (1) | CA2490907C (pt) |
DE (1) | DE60329918D1 (pt) |
DK (1) | DK1533304T3 (pt) |
ES (1) | ES2337995T3 (pt) |
MX (1) | MXPA04012845A (pt) |
PT (1) | PT1533304E (pt) |
RU (1) | RU2315043C2 (pt) |
WO (1) | WO2004002963A1 (pt) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
US7375175B2 (en) | 2002-08-19 | 2008-05-20 | National Starch And Chemical Investment Holding Corporation | Dispersions containing living radicals |
CA2513583C (en) * | 2003-01-17 | 2012-03-20 | Wisconsin Alumni Research Foundation | Modified retinoid compounds and their uses |
GB2400101A (en) * | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
WO2004110452A1 (en) * | 2003-06-13 | 2004-12-23 | Novartis Ag | 2-aminopyrimidine derivatives as raf kinase inhibitors |
JPWO2005019238A1 (ja) * | 2003-08-22 | 2006-10-19 | 明治製菓株式会社 | 新規アザライド及びアザラクタム誘導体とその製造法 |
CN100526298C (zh) * | 2003-12-25 | 2009-08-12 | 日本新药株式会社 | 酰胺衍生物及医药品 |
US8735415B2 (en) | 2004-09-09 | 2014-05-27 | Natco Pharma Limited | Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide |
EP1786799B1 (en) | 2004-09-09 | 2012-07-04 | Natco Pharma Limited | Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
GB0512091D0 (en) * | 2005-06-14 | 2005-07-20 | Novartis Ag | Organic compounds |
KR100674813B1 (ko) * | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | N-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
MX2009006536A (es) * | 2006-12-22 | 2009-06-26 | Novartis Ag | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. |
ES2607794T3 (es) | 2007-06-07 | 2017-04-04 | Intra-Cellular Therapies, Inc. | Compuestos heterocíclicos novedosos y usos de los mismos |
JP5710251B2 (ja) | 2007-06-07 | 2015-04-30 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規ヘテロ環化合物およびその使用 |
US8415358B2 (en) | 2007-09-17 | 2013-04-09 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
WO2009124037A1 (en) * | 2008-03-31 | 2009-10-08 | Teva Pharmaceutical Industries Ltd. | Processes for preparing sunitinib and salts thereof |
CA2753637A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Ag | Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak) |
SG10201507362TA (en) | 2009-08-05 | 2015-10-29 | Intra Cellular Therapies Inc | Novel Regulatory Proteins And Inhibitors |
KR20120099650A (ko) | 2009-10-23 | 2012-09-11 | 노파르티스 아게 | Bcr-abl, c-kit, ddr1, ddr2 또는 pdgf-r 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법 |
JO3634B1 (ar) | 2009-11-17 | 2020-08-27 | Novartis Ag | طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r |
WO2013138430A1 (en) * | 2012-03-14 | 2013-09-19 | Indiana University Research And Technology Corporation | Compounds and methods for treating leukemia |
ES2821529T3 (es) | 2012-11-21 | 2021-04-26 | Ptc Therapeutics Inc | Derivados de 4,6-diamino-pirimidina como inhibidores de Bmi-1 para el tratamiento del cáncer |
NZ718055A (en) | 2013-08-30 | 2020-01-31 | Ptc Therapeutics Inc | Substituted pyrimidine bmi-1 inhibitors |
WO2015076801A1 (en) * | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted triazine bmi-1 inhibitors |
WO2015076800A1 (en) | 2013-11-21 | 2015-05-28 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine bmi-1 inhibitors |
WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
CN110343092B (zh) * | 2017-01-20 | 2021-03-02 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物 |
US10875853B2 (en) | 2017-01-20 | 2020-12-29 | Shenzhen Targetrx, Inc. | (Hetero)arylamide compound for inhibiting protein kinase activity |
CA3132730A1 (en) * | 2019-03-05 | 2020-09-10 | Hongyi & Associates Llc | Compounds for treating neurodegenerative diseases and cancers |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW225528B (pt) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
GB0022438D0 (en) * | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
-
2003
- 2003-06-27 AT AT03738555T patent/ATE447560T1/de active
- 2003-06-27 PT PT03738555T patent/PT1533304E/pt unknown
- 2003-06-27 WO PCT/JP2003/008192 patent/WO2004002963A1/ja active Application Filing
- 2003-06-27 US US10/519,722 patent/US7494997B2/en not_active Expired - Lifetime
- 2003-06-27 BR BRPI0312288A patent/BRPI0312288B8/pt active IP Right Grant
- 2003-06-27 DK DK03738555.6T patent/DK1533304T3/da active
- 2003-06-27 EP EP03738555A patent/EP1533304B1/en not_active Expired - Lifetime
- 2003-06-27 RU RU2005102098/04A patent/RU2315043C2/ru active
- 2003-06-27 ES ES03738555T patent/ES2337995T3/es not_active Expired - Lifetime
- 2003-06-27 DE DE60329918T patent/DE60329918D1/de not_active Expired - Lifetime
- 2003-06-27 JP JP2004517313A patent/JP4552650B2/ja not_active Expired - Lifetime
- 2003-06-27 CA CA2490907A patent/CA2490907C/en not_active Expired - Lifetime
- 2003-06-27 MX MXPA04012845A patent/MXPA04012845A/es active IP Right Grant
- 2003-06-27 AU AU2003246100A patent/AU2003246100A1/en not_active Abandoned
- 2003-06-27 CN CNB038201461A patent/CN100343237C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE60329918D1 (de) | 2009-12-17 |
ES2337995T3 (es) | 2010-05-03 |
PT1533304E (pt) | 2010-02-08 |
MXPA04012845A (es) | 2005-02-24 |
CN1678590A (zh) | 2005-10-05 |
EP1533304A4 (en) | 2006-10-18 |
AU2003246100A1 (en) | 2004-01-19 |
RU2315043C2 (ru) | 2008-01-20 |
ATE447560T1 (de) | 2009-11-15 |
BRPI0312288B8 (pt) | 2021-05-25 |
US20060014742A1 (en) | 2006-01-19 |
WO2004002963A1 (ja) | 2004-01-08 |
CA2490907C (en) | 2010-08-24 |
JPWO2004002963A1 (ja) | 2005-10-27 |
BRPI0312288B1 (pt) | 2019-01-02 |
EP1533304B1 (en) | 2009-11-04 |
US7494997B2 (en) | 2009-02-24 |
JP4552650B2 (ja) | 2010-09-29 |
CA2490907A1 (en) | 2004-01-08 |
CN100343237C (zh) | 2007-10-17 |
EP1533304A1 (en) | 2005-05-25 |
DK1533304T3 (da) | 2010-03-22 |
RU2005102098A (ru) | 2005-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0312288A (pt) | Derivados de amidas | |
BRPI0418074B8 (pt) | derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos | |
BRPI0515446A (pt) | amidas bicìclicas como inibidores de cinases | |
ATE206390T1 (de) | Cyclobutan-derivate als inhibitoren der squalen- synthase und der protein farnesyltransferase | |
BR9803883A (pt) | Derivado de amida. | |
BRPI0513863A (pt) | derivados de uréia cìclica substituìda por heterociclo, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase | |
BR0114436A (pt) | Composto com anel de cinco elementos contendo nitrogênio alifático | |
BRPI0510598A (pt) | compostos de amida de aril ou heteroaril substituìdos | |
BR0307606A (pt) | Derivados de piperazinila, piperidinila e morfolinila como inibidores de histona desacetilase | |
BR0316350A (pt) | Diaminotriazóis úteis como inibidores de proteìna cinases | |
BRPI0616574A2 (pt) | derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2 | |
BR0113448A (pt) | Composto da fórmula ou um sal ou solvato deste ou um derivado destes fisiologicamente funcional, composição farmacêutica, uso do composto ou de um sal ou solvato deste ou de um derivado destes fisiologicamente funcional, e , métodos para tratar uma condição ou estado de doença mediados pela p38 quinase ou mediados pelas citoquinas, e mediados pela jnk quinase ou mediados pelas citoquinas, e ,para tratar duas ou mais condições ou doenças independentemente mediadas pela atividade da p38 e da jnk quinase | |
BR0207025A (pt) | Derivado de isoxazolina e herbicida contendo o mesmo como o ingrediente ativo | |
BRPI0821653B8 (pt) | composto de piridina substituída com anel heterocíclico e grupo fosfonoximetila ou um sal do mesmo, composição farmacêutica compreendendo-os e uso dos mesmos para tratar uma doença fungíca | |
BRPI0411414A (pt) | derivados de quinolil amida como antagonistas de cdr-5 | |
CY1106522T1 (el) | Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο | |
BR0210874A (pt) | Derivados de tiazol-benzamida e composições farmacêuticas para a inibição da proliferação celular e métodos para o seu uso | |
BRPI0515851A (pt) | composto de pirimidona | |
ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
TW200724166A (en) | Wrinkle-improving agent | |
BR0212435A (pt) | Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase | |
BRPI0408353A (pt) | composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto | |
BRPI0408591A (pt) | derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda | |
BR0308109A (pt) | Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila | |
BR0309558A (pt) | Derivados de quinazolina e medicamentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2261 DE 06/05/2014 |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/01/2019, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/06/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |